Free Trial
NASDAQ:ACAD

ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis

$18.13
+0.38 (+2.14%)
(As of 07/22/2024 ET)
Today's Range
$17.79
$18.13
50-Day Range
$14.62
$18.62
52-Week Range
$14.55
$32.59
Volume
1.96 million shs
Average Volume
1.76 million shs
Market Capitalization
$3.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.59

ACADIA Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.76 Rating Score
Upside/​Downside
57.7% Upside
$28.59 Price Target
Short Interest
Healthy
7.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.47mentions of ACADIA Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$348,697 Sold Last Quarter
Proj. Earnings Growth
79.31%
From $0.58 to $1.04 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.34 out of 5 stars

Medical Sector

130th out of 894 stocks

Pharmaceutical Preparations Industry

48th out of 426 stocks

ACAD stock logo

About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ACAD Stock Price History

ACAD Stock News Headlines

This AI made her leave her job
This AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and finds hot stocks that you probably have never even heard of… …it recommends the best potential strategy to use on the names it finds (with historical data to prove it)
This AI made her leave her job
This AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and finds hot stocks that you probably have never even heard of… …it recommends the best potential strategy to use on the names it finds (with historical data to prove it)
Acadia Pharmaceuticals: Back In The Buy Zone
Oppenheimer Keeps Their Buy Rating on Intellia Therapeutics (NTLA)
See More Headlines
Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/08/2024
Today
7/23/2024
Next Earnings (Estimated)
8/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ACAD
Employees
597
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.59
High Stock Price Target
$42.00
Low Stock Price Target
$19.00
Potential Upside/Downside
+57.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.76
Research Coverage
17 Analysts

Profitability

Net Income
$-61,290,000.00
Pretax Margin
1.83%

Debt

Sales & Book Value

Annual Sales
$726.44 million
Book Value
$2.63 per share

Miscellaneous

Free Float
118,463,000
Market Cap
$3.00 billion
Optionable
Optionable
Beta
0.38
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives


ACAD Stock Analysis - Frequently Asked Questions

How have ACAD shares performed this year?

ACADIA Pharmaceuticals' stock was trading at $31.31 at the beginning of 2024. Since then, ACAD stock has decreased by 42.1% and is now trading at $18.13.
View the best growth stocks for 2024 here
.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its earnings results on Wednesday, May, 8th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of $0.04 by $0.06. The company's revenue for the quarter was up 73.8% on a year-over-year basis.

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees.

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' top institutional investors include M&G Plc (0.21%), Neo Ivy Capital Management (0.12%), Hennion & Walsh Asset Management Inc. (0.06%) and SG Americas Securities LLC (0.06%). Insiders that own company stock include Bros Advisors Lp Baker, Stephen Davis, Srdjan R Stankovic, Austin D Kim, Brendan Teehan, Mark C Schneyer, James Kihara and Laura Brege.
View institutional ownership trends
.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA) and Alibaba Group (BABA).

This page (NASDAQ:ACAD) was last updated on 7/23/2024 by MarketBeat.com Staff

From Our Partners